RoboSense Adds GWM WEY to Its List of Design Wins on Top of 50+ Models
14.9.2022 17:02:00 EEST | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems today announced that it will provide LiDAR for Great Wall Motor WEY Mocha DHT-PHEV LiDAR Edition. On the same day, WEY Mocha DHT-PHEV LiDAR Edition was officially launched at the 25th Chengdu International Auto Show.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220826005302/en/
Great Wall Motor WEY Mocha SUV equipped with two RS-LiDAR-M1
Based on WEY’s Mocha DHT-PHEV LiDAR Edition, RoboSense, together with Haomo.AI and Qualcomm, jointly created the urban driving assistance solution NOH for WEY. In particular, RoboSense second-generation smart solid-state LiDAR (RS-LiDAR-M1) are deployed under the headlights on both sides of the vehicle, one on each side, which give Mocha DHT-PHEV accurate perception capabilities and provide an extra level of perception safety redundancy. Adopting the perception-focused technology path, Mocha DHT-PHEV can perceive, think and make decisions like a human being, and full coverage of China’s high-speed and urban road commuting scenes is realized - smarter intelligence for driving assistance; safer and cozier driving experience for consumers.
With the large-scale application of intelligent driving technologies, the increasingly more complex application scenarios put higher automotive-grade reliability requirements for LiDAR on the front side of the vehicle body. Mocha DHT-PHEV’s intelligent driving application scenarios cover all kinds of high-speed and urban road conditions. Complex road conditions will bring various challenges to LiDAR.
RS-LiDAR-M1 adopts highly-integrated design, and has passed a series of reliability tests in accordance with strict passenger vehicle standards, including mechanical shock, random vibration, high-pressure water impact, high and low temperature operation, high and low temperature damp heat, solar radiation, EMC, chemical anti-corrosion, salt spray and other tests. It fully meets the safety, reliability and service life requirements of Mocha DHT-PHEV in complex high-speed and urban road scenarios.
Meanwhile, thanks to the revolutionary 2D MEMS LiDAR technology platform, M1’s unique smart “GAZE” function can dynamically switch scanning modes according to different scenarios such as high-speed railways and urban areas, giving urban NOH ADAS solution the differentiated scenario perception capability, safeguarding and ensuring the smart driving experience of Mocha DHT-PHEV LiDAR Edition.
With its leading technological strengths in the field of LiDAR, RoboSense has obtained design wins for more than 50 models from companies including Great Wall Motor, BYD, FAW Hongqi, GAC AION, ZEEKR, WM Motor, Lotus Cars, Lucid Motors, Inceptio Technology and Zhito Technology. RoboSense will always pursue technological innovation and keep promoting the large-scale production of smart vehicles.
About RoboSense
RoboSense is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. Its mission is to innovate outstanding hardware and AI capabilities to create smart solutions that enable robots, including autonomous vehicles, to have perception capabilities superior to humans.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220826005302/en/
Contact information
Grace Ye
media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom